Article
Marinus parts with priority review voucher, selling skip-the-line pass to Novo Nordisk for $110M
Rating:
0.0
Views:
91
Likes:
1
Library:
1
Marinus Pharmaceuticals is using a priority review voucher granted four months ago as a financial life preserver, selling the accelerated review pass designated for rare pediatric diseases to Novo | Marinus is selling off a priority review voucher to Novo Nordisk for $110 million. The company plans to use the additional funds to pay for two ongoing phase 3 trials and the launch of its new seizure med, Ztalmy.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value